Disclosed are compounds having Formula (I) and the compositions and methods thereof for treating or preventing a viral infection mediated at least in part by a virus in the
Flaviviridae
family of viruses, wherein A, R
2
, m, R, V, W, T, Z, R
1
, Y, and p are disclosed herein.
A compound of the following formula or a pharmacologically acceptable salt thereof:
1
wherein A represents a phenyl group or the like, B represents an aryl group or the like, X represents an oxygen atom or the like, and n represents 0 or 1. The compound is a PPAR &ggr; modulator which is a therapeutic agent for retrograde osteoporosis in which excessive differentiation of adipocytes is inhibited and formation and differentiation of osteoblasts from stem cells is facilitated, and for diabetes mellitus without characteristics such as excessive adipogenesis, liver dysfunction, vascular disorders, heart diseases and the like.
The present invention provides Quinazolinedione derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.
Microwave-Induced Solvent-Free Synthesis and Antifungal Screening of Novel Spiro Heterocyclic Systems Containing 3,5-Diphenyl-7H-thiazolo[3,2-a]pyrimidine and Indolin-2-one
microwave-induced technique has been developed for the synthesis of a series of novel spiro indoline-based heterocycles (7a–g) at atmospheric pressure in an open vessel using an environmentally benign procedure. This rapid method produces pure products in good yields within a few minutes in comparison to the conventional procedure developed for the synthesis of these heterocycles. The synthesized compounds
[EN] PYRIMIDINEDIONE-FUSED HETEROCYCLIC COMPOUNDS AS TRPA1 MODULATORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES FUSIONNÉS À UNE PYRIMIDINE DIONE EN TANT QUE MODULATEURS DE TRPA1
申请人:GLENMARK PHARMACEUTICALS SA
公开号:WO2010125469A1
公开(公告)日:2010-11-04
The present invention is related to novel pyrimidinedione-fused heterocyclic compounds as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.